Repaglinide should be taken 15-30 minutes before each main meal. This timing aligns the drug’s peak insulin-stimulating effect with post-prandial glucose absorption, helping to minimise blood-sugar spikes.
Yes, it is often combined with metformin or a thiazolidinedione to achieve better glycaemic control. However, co-administration with another insulin secretagogue (e.g., a sulfonylurea) may increase hypoglycaemia risk and requires careful monitoring.
Both stimulate insulin release, but repaglinide acts more rapidly and has a shorter duration of action. This allows dose flexibility for each meal and reduces the risk of prolonged hypoglycaemia compared with longer-acting sulfonylureas.
Patients with eGFR ≥ 30 mL/min/1.73 m² can use Prandin, but the starting dose should be low (0.5 mg) and titrated cautiously. Renal function should be monitored regularly.
Consume 15-20 g of fast-acting carbohydrate (e.g., glucose tablets, fruit juice) immediately. Re-check blood glucose after 15 minutes; if still low, repeat the carbohydrate dose. Seek medical help if the episode does not improve or if the person is unconscious.
Yes. Strong CYP2C8 inhibitors (e.g., gemfibrozil) can raise repaglinide levels, while CYP3A4 inducers (e.g., rifampicin) may lower them. Dose adjustments or alternative therapies should be discussed with your prescriber.
No. The tablets are designed to be swallowed whole with water. Crushing, chewing, or splitting may alter the release profile and increase hypoglycaemia risk.
Prandin is a prescription medicine; you should carry it in its original labelled container, accompanied by a copy of the prescription or a letter from your doctor. In the UK, you may need to declare it at customs if travelling outside the EU, but generally there are no restrictions for personal use.
Brand-name Prandin is typically priced higher than generic versions of repaglinide due to patent and marketing costs. NHS pricing guidelines encourage the use of generics when clinically appropriate, but cost differences vary by pharmacy and region.
Do not take expired medication. Dispose of them via a pharmacy medicine-take-back scheme or follow local council instructions for safe drug disposal. Avoid flushing tablets down the toilet unless specifically advised.
Prandin is a brand-name medication that contains repaglinide as its active ingredient. It belongs to the class of short-acting insulin secretagogues and is used to improve blood-sugar control in adults with type 2 diabetes mellitus (T2DM). In the United Kingdom, Prandin is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as a pill in three strengths: 0.5 mg, 1 mg, and 2 mg.
Repaglinide stimulates the pancreas to release more insulin in response to meals. It binds to the sulfonylurea receptor-1 (SUR-1) subunit of the ATP-sensitive potassium (K⁺) channels on pancreatic β-cells. This action:
Because repaglinide’s effect is short-lasting (onset within 15 minutes, peak at about 1 hour, duration 3-5 hours), it is taken before each main meal to target post-prandial glucose spikes. The drug is absorbed quickly, with an oral bioavailability of roughly 56 %. It is metabolised primarily by the liver enzymes CYP2C8 and CYP3A4 and excreted in the urine and bile.
Approved Indication (MHRA)
Repaglinide is not approved for type 1 diabetes, gestational diabetes, or diabetic emergencies such as ketoacidosis.
No robust peer-reviewed evidence supports routine off-label use of repaglinide for conditions other than T2DM. While some small studies have explored its role in pre-diabetes or in combination with insulin therapy, these uses are not approved by the MHRA and should only be considered under specialist supervision.
Patients should disclose all prescription medicines, over-the-counter drugs, herbal products, and supplements to their healthcare provider before starting Prandin.
Standard dosing:
Begin with 0.5 mg taken before each main meal (breakfast, lunch, dinner).
The dose may be increased by 0.5 mg increments based on blood-glucose response, up to a maximum of 4 mg per day (e.g., 2 mg before breakfast and dinner).
The tablet should be swallowed whole with a glass of water; crushing or chewing is not recommended.
Special populations:
Elderly or patients with moderate renal/hepatic impairment: Start with the lowest dose (0.5 mg) and titrate cautiously.
Renal adjustment: If eGFR falls below 30 mL/min/1.73 m², dose reductions and close glucose monitoring are advised.
Pregnancy & lactation: Generally avoided; insulin therapy is preferred.
Missed dose: If a meal is delayed or omitted, skip the corresponding repaglinide dose; do not double the next dose.
Overdose: Symptoms may include severe hypoglycaemia, shakiness, sweating, and confusion. Seek emergency medical help; treatment includes administration of rapid-acting glucose (oral or intravenous) and monitoring of blood glucose.
Discontinuation: Gradual tapering is not required, but abrupt cessation may lead to hyperglycaemia. Follow up with a clinician to adjust the overall diabetes regimen.
This article provides educational information about Prandin (repaglinide) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
